Document is current

Article History

Received: 22 October 2025

Accepted: 26 November 2025

First Online: 24 December 2025

Declarations

:

: Andrea Bauer has been a speaker, advisor, or investigator, and/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Blueberry Therapeutics, Celldex, Centogene, Escient, Galderma, Genentech, Gilead, Incyte, Jasper, LEO Pharma A/S, Lilly, L’Oréal, Novartis, Pfizer, Sanofi, Regeneron, and Takeda. Marie-Louise Schuttelaar has been a consultant, advisory board member, investigator, and/or speaker for AbbVie, Amgen, Eli Lilly, Galderma, LEO Pharma A/S, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. Keith Baranowski, Ursula Plohberger, and Laura Sørensen, are shareholders and employees of LEO Pharma A/S. Margitta Worm reports grants and personal fees from AbbVie Deutschland, Allergopharma, Aimmune, ALK-Abello, Almirall S. A., Amgen GmbH, Biotest, Bristol-Myers Squibb GmbH & Co., DBV Technologies, KGaA, LEO Pharma A/S, Lilly Deutschland, Mylan Germany, Novartis, Pfizer Deutschland GmbH, Regeneron Pharmaceuticals, and Sanofi Aventis, outside the submitted work and is past WAO co-chair of the anaphylaxis committee.

: In the 10 countries where DELTA 1 and DELTA 2 were conducted, prior to screening of patients, the institutional review board or independent ethics committee at all centres approved the protocol, investigator’s brochure, and any information provided to patients (Table  ). The trials were conducted according to the ethical principles of the Declaration of Helsinki. All patients provided written informed consent.